bioRxivBioengineering
mRNA trans-splicing dual AAV vectors for (epi)genome editing and gene therapy
L. M. Riedmayr, K. S. Hinrichsmeyer, S. B. Thalhammer, N. Karguth, S. Boehm, D. M. Mittas, V. J. Weber, D. Otify, V. Splith, M. Bruemmer, N. Boon, J. Wijnholds, V. Mehlfeld, S. Michalakis, S. Fenske, M. Biel, E. Becirovic
Abstract
Large genes including several CRISPR-Cas modules, such as gene activators (CRISPRa), require dual adeno-associated viral (AAV) vectors for an efficient in vivo delivery and expression. Current dual AAV vector approaches have important limitations, e.g., low reconstitution efficiency, production of alien proteins, or low flexibility in split site selection. Here, we present a dual AAV vector technology based on reconstitution via mRNA trans-splicing (REVeRT). REVeRT is flexible in split site selection and can efficiently reconstitute different split genes in numerous in vitro models, in human organoids, and in vivo. Furthermore, REVeRT can functionally reconstitute a CRISPRa module targeting genes in various mouse tissues and organs in single or multiplexed approaches upon different routes of administration. Finally, intravitreal supplementation of ABCA4 via REVeRT improves retinal degeneration and function in a mouse model of Stargardt disease. Due to its flexibility and efficiency REVeRT harbors great potential for basic research and clinical applications.
- organism: mouse
- assay: CRISPR screen
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Comparison of CRISPR/Cas endonucleases for in vivo retinal gene editing.
F. Li, K. Wing, … A. W. Hewitt·bioRxiv·Jun 9, 2020
- Double-Strand Break Repair Pathways Differentially Affect Processing and Transduction by Dual AAV Vectors
Anna C. Maurer, Brian Benyamini, … Robert Tjian·Nature CommunicationsPeer-reviewed·Feb 11, 2025
- AAV-mediated CRISPR/Cas gene editing of retinal cells in vivo.
Sandy SC Hung, Vicki Chrysostomou, … Alex Hewitt·Investigative Opthalmology & Visual SciencePeer-reviewed·Jun 29, 2016
- Multi-step engineered adeno-associated virus enables whole-brain mRNA delivery
- Efficacy and dynamics of self-targeting CRISPR/Cas constructs for gene editing in the retina.
Li Fan, Sandy S. C. Hung, … Guei‐Sheung Liu·Human Gene TherapyPeer-reviewed·Aug 2, 2019
- Mannose-coupled AAV2: a second generation AAV vector for increased retinal gene therapy efficiency
M. MEVEL, V. Pichard, … O. Adjali·bioRxiv·Dec 1, 2022